DICE Therapeutics
Jessica Defreese has a diverse work experience in the pharmaceutical industry. Jessica is currently working as a Senior Director of Project Management at DICE Therapeutics. Previously, they worked at Genentech, where they held various roles including Senior Principal Program Manager, Principal Program Manager, Senior Program Manager, Program Manager, and Scientific Manager. At Genentech, they demonstrated their adaptability by leading a team that successfully designed and executed a COVID-19 trial in less than 12 months. Jessica also prioritized diversity, equity, and inclusion within the R&D organization. Prior to their time at Genentech, they worked as a Research Scientist at Exelixis and as a Senior Research Investigator and Research Investigator at Bristol-Myers Squibb.
Jessica Defreese completed their education with a Bachelor of Science degree in Chemical Engineering from the University of Illinois Urbana-Champaign in 2000. Jessica then pursued further studies and obtained a Ph.D. in Chemical Engineering from the University of California, Berkeley between 2000 and 2005. In addition to their academic qualifications, Jessica also holds a certification as a Project Management Professional from the Project Management Institute. The specific month and year of when they obtained this certification are not provided.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.